What is the Trivalent Salmonella Conjugate Vaccine (TSCV)?
It is a novel vaccine designed to protect against both typhoid fever and invasive non-typhoidal Salmonella (iNTS) infections.
Yanuki
ARTICLE DETAIL
Novel Salmonella Vaccine Shows Promise in Clinical Trial | Femtech Market Growth to $26 Billion by 2033: Key Insights and Opportunities | Preparing for Daylight Saving Time 2026: What You Need to Know | Oscar-Nominated Directors Highlight Workers at a Women's Health Clinic in 'The Devil Is Busy' | Trump Spotted with Rash on Neck: Possible Causes and Theories | Olympic Village Condom Shortage: A Hot Topic at the 2026 Winter Games | Talcum Powder and Cancer: Unveiling the Connection | Drug-Resistant Typhoid Fever: An Ancient Killer Returns | RFK Jr.'s CDC Panel to Discuss Covid Vaccine Injuries | Novel Salmonella Vaccine Shows Promise in Clinical Trial | Femtech Market Growth to $26 Billion by 2033: Key Insights and Opportunities | Preparing for Daylight Saving Time 2026: What You Need to Know | Oscar-Nominated Directors Highlight Workers at a Women's Health Clinic in 'The Devil Is Busy' | Trump Spotted with Rash on Neck: Possible Causes and Theories | Olympic Village Condom Shortage: A Hot Topic at the 2026 Winter Games | Talcum Powder and Cancer: Unveiling the Connection | Drug-Resistant Typhoid Fever: An Ancient Killer Returns | RFK Jr.'s CDC Panel to Discuss Covid Vaccine Injuries
Health / Vaccines
Novel Salmonella Vaccine Shows Promise in Clinical Trial
A novel trivalent vaccine targeting typhoid fever and invasive non-typhoidal Salmonella (iNTS) infections has demonstrated promising safety and robust immune responses in a Phase 1 human trial. Developed by the University of Maryland and Bh...
Key Insights
- A trivalent Salmonella conjugate vaccine (TSCV) has shown promising results in a Phase 1 trial, demonstrating safety and strong immune responses in healthy adults.
- The vaccine targets Salmonella enterica serovar Typhi (typhoid fever) and serovars Typhimurium and Enteritidis (iNTS infections), which account for about 90% of iNTS infections in young children.
- TSCV combines the Vi capsular polysaccharide from Bharat Biotech’s licensed typhoid conjugate vaccine (Typbar TCV) with tetanus toxoid and core-plus-O-polysaccharides from the two most prevalent iNTS serovars, conjugated to flagellin carrier proteins.
- Trial results showed no serious adverse events among TSCV recipients, with mild to moderate reactions reported. All vaccine recipients developed robust immune responses to the three polysaccharide components.
- Antibodies remained at levels four times higher than baseline in vaccine recipients more than a year later, indicating long-lasting immunity.
In-Depth Analysis
The investigational Trivalent Salmonella Conjugate Vaccine (TSCV) represents a significant advancement in combating typhoid fever and non-typhoidal Salmonella infections. These infections pose a substantial threat, particularly in sub-Saharan Africa, where they contribute to high rates of childhood illness and mortality.
The TSCV vaccine leverages sugar molecules from Salmonella Typhi bacteria (typhoid fever) and two common serotypes of invasive non-typhoidal Salmonella enterica, which are frequently implicated in U.S. outbreaks linked to contaminated poultry, eggs, and produce. The combination of these components aims to provide broad protection against major invasive Salmonella pathogens.
In the Phase 1 trial, 22 healthy adults received either a low dose (6.25 µg), a high dose (12.5 µg) of the vaccine, or a placebo. The results indicated that the vaccine was well-tolerated, with only mild injection site discomfort reported. More importantly, all vaccinated participants developed strong immune responses to the three targeted Salmonella strains, while placebo recipients did not. This immune response also involved white blood cells, suggesting potential for both localized and systemic protection against Salmonella.
The study also noted that some participants showed pre-existing Salmonella antibodies, likely from prior exposure through foodborne sources, which may enhance vaccine-induced immunity. This highlights the potential for the vaccine to be particularly effective in regions where Salmonella exposure is common.
Developed in collaboration with Bharat Biotech International Ltd., TSCV builds on the World Health Organization (WHO)-prequalified Typbar TCV platform. The next steps involve further trials, including studies in young children, who are the most vulnerable population.
FAQ
How does the vaccine work?
The vaccine combines sugar molecules from Salmonella Typhi bacteria and two common serotypes of invasive non-typhoidal Salmonella enterica, linked to proteins that enhance the body’s immune recognition.
What were the results of the Phase 1 trial?
The vaccine was safe and well-tolerated, with all vaccinated participants developing strong immune responses to the targeted Salmonella strains.
Who developed the vaccine?
The vaccine was developed jointly by the University of Maryland’s Center for Vaccine Development and Global Health (CVD) and Bharat Biotech International Limited.
Takeaways
- The TSCV vaccine shows promise as a potential solution for preventing typhoid fever and invasive non-typhoidal Salmonella infections, particularly in children.
- The vaccine has demonstrated safety and strong immune responses in initial human trials.
- Further research and trials are planned to confirm the vaccine’s effectiveness and safety in vulnerable populations, such as young children.
- This advancement could significantly impact global public health by reducing the burden of Salmonella-related diseases.
Discussion
Do you think this vaccine will be a game-changer in combating typhoid and Salmonella infections? Share your thoughts in the comments below!
Share this article with others who need to stay ahead of this trend!
Sources
Disclaimer
This article was compiled by Yanuki using publicly available data and trending information. The content may summarize or reference third-party sources that have not been independently verified. While we aim to provide timely and accurate insights, the information presented may be incomplete or outdated.
All content is provided for general informational purposes only and does not constitute financial, legal, or professional advice. Yanuki makes no representations or warranties regarding the reliability or completeness of the information.
This article may include links to external sources for further context. These links are provided for convenience only and do not imply endorsement.
Always do your own research (DYOR) before making any decisions based on the information presented.